US3642993A - Pharmaceutical composition containing 2-methyl - 5 - phenyl - 1 2-dihydro-3h-2-benzazepine for treatment of a condition associated with anxiety or tension - Google Patents

Abstract

A PHARMACEUTICAL COMPOSITION COMPRISING 2-METHYL-5PHENYL-1,2-DIHYDRO-3H-BENZAZEPINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN ASSOCIATION WITH A PHARMACEUTICAL CARRIER. THE UTILITY OF THE COMPOSITION IS TO RELIEVE CONDITIONS ASSOCIATED WITH ANXIETY, TENSION OR THE EMOTIONAL DISTURBANCES.

Description

United States Patent 36,028/ 69 Int. Cl. A61v 27/00 US. Cl. 424--244 4 Claims ABSTRACT OF THE DISCLOSURE A pharmaceutical composition comprising 2-methyl-5- phenyl-1,2-dihydro-3H-benzazepine, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutical carrier.

The utility of the composition is to relieve conditions associated with anxiety, tension or the emotional disturbances.

This invention relates to therapeutic compositions. We have found, according to the invention, that 2- methyl 5 phenyl-1,2-dihydro-3H-Z-benzazepine of the formula:

and non-toxic pharmaceutically acceptable salts thereof have a useful effect on the central nervous system. In particular they have a sedative-hypnotic efi'ect and may be used in the treatment of conditions associated with anxiety, tension or other emotional disturbances.

In small animal species such as mice and rats the administration of an oral dose of 2550 mg. in the form of the hydrochloride produced moderate to marked depression which was devoid of associated stimulant activity, the duration of action exceeding 4 hours.

The invention therefore provides a pharmaceutical composition comprising a compound of Formula I above, or a non-toxic pharmaceutically acceptable salt in association with a pharmaceutical carrier.

The term pharmaceutical carrier as used herein does not extend to common solvents as normally used but is intended to extend to such solvents when they have been particularly adapted for pharmaceutical use, for example by being rendered sterile or non-pyrogenic. It is also to be made clear that the invention extends to such solvents when they are used in a particular form for administration such as in capsules and the like.

The compositions may be prepared by techniques well known in the pharmaceutical art. Suitable dosage forms include capsules pressed or coated, tablets, syrups and aqueous suspensions. The compositions may also be presented in rectal suppository form. They may alsocontain other active ingredients. Preferably the composition is in unit dosage form which expression as used herein means a physically discrete unit containing a predetermined dose of the active ingredient in association with a ice pharmaceutically acceptable carrier or excipient. The unit dosage form may contain from 25-500 mg. of the active ingredient.

The daily dose of the active ingredient may be from 0.5 mg./kg. 20 mg./ kg. depending on the clinical state of patient and response to therapy.

The compound may be prepared by methods described by Harcourt and Brooks in J. Chem. Soc. 1969 (C) 625. The salts may be made from the base or from other salts by conventional methods.

The following examples illustrate the invention (where reference is made to Compound I this is the compound of Formula I above).

EXAMPLE 1 Capsules To prepare 10,000 capsules each containing 5 mg. of Compound I.Mix together 50 g. Compound I and 850 g. of dried micro-crystalline cellulose B.-P.C. Fill the powder into hard gelatin capsules size No. 4 so that each capsule contains mg. of the mixture.

To prepare 10,000 capsules each containing 10 mg. of Compound I.Mix together g. Compound I and 1,100 g. of dried micro-crystalline cellulose B.P.C. Fill the powder into hard gelatin capsules size No. 3 so that each capsule contains mg. of the mixture.

EXAMPLE 2 Tablets To prepare 20,000 tablets each containing 50 mg. of Compound I.--Mix together 1 kg. Compound I, 2.47 kg. of lactose and 250 g. of maize starch and suflicient of a 1% aqueous solution of sodium carboxymethylcellulose to produce a damp cohesive mass. Granulate the damp mass by passing through a suitable comminuting mill and dry the granules at 50 C. in a fluidised bed dryer. Mix the dried granules with 250 g. of dried maize starch and 30 g. of magnesium stearate. Compress the lubricated granules on a suitable tableting machine to produce biconvex tablets in diameter and each weighing about 200 mg.

The tablets may be film coated or sugar coated if required.

To prepare 20,000 tablets each containing 200 mg. of Compound I.-Mix together 4.0 kg. compound I, 2.9 kg. lactose and 500 g. of maize starch and suflicient of a 1% aqueous solution of sodium carboxymethylcellulose to produce a damp cohesive mass. Granulate the damp mass by passing through a suitable comminuting mill and dry the granules at 50 C. in a fluidised bed dryer. and 50 g. magnesium stearate. Compress the lubricated Mix the dried granules with 500 g. of dried maize starch granules on a suitable tableting machine to produce biconvex in diameter and each weighing about 400 mg.

The tablets may be film coated or sugar coated if required.

EXAMPLE 3 Syrup To prepare a syrup suitable for oral administration containing Compound I HCl equivalent to 100 mg. of Compound I per 5 ml.--Heat 6 litres of distilled water to 70 C. and in it dissolve 15 g. of methyl parahydroxybenzoate and 2 g. of propyl parahydroxybenzoate followed by 5 kg. of sucrose. Cool the syrup to 40 C. and dissolve 3 g. of sodium saccharin, 50 g. of citric acid, 20 g. of sodium acid citrate, 30 ml. of lemon flavour, 10 g. of tartrazine and 231 g. of compound I, HCl. When solution is complete make up to 10 litres with distilled water.

3 EXAMPLE 4 Suspension To prepare an aqueous suspension suitable for oral administration containing Compound I pamoate equivalent to 50 mg. of Compound I per 5 ml.--Dissolve 100 g. of compound I in 1 litre of distilled water by the addition of the requisite amount of hydrochloric acid. In a separate litre of water dissolve 160 g. of disodium pamoate. Mix together these two solutions to produce a suspension of Compound I pamoate.

Heat to 70 C. 6 litres of distilled water and in it dissolve 15 g. of methyl parahydroxybenzoate and 2 g. of propyl parahydroxybenzoate. Mix together 4 kg. of sucrose and 20 g. of Carbopol 934 and add this to the hot solution prepared earlier. When the sucrose has dissolved and the Carbopol has been well dispersed add sufiicient of a freshly prepared 10% aqueous solution of sodium hydroxide to raise the pH to 7.0. Continue stirring until a smooth gel has formed ensuring that the stirrer does not entrain any air into the gel. Cool the gel to 40 C. and carefully dissolve in the gel 30 ml. of a suitable flavour and 5 g. of amaranth. Add the suspension of Compound I pamoate and mix carefully until a homogeneous product has been produced. Make up to 10 litres with further distilled water.

What is claimed is:

1. A pharmaceutical composition for relieving a condition associated with anxiety, tension or the like emotional disturbances comprising in unit dosage form from -500 mg. of 2-methyl-5-phenyl-1,Z-dihydro-3H-2-benzazepine, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutical carrier.

2. A composition as claimed in claim 1 in the form of a pressed or coated capsule, a tablet, a syrup or an aqueous suspension.

3. A method of treating a patient to relieve a condition associated with anxiety, tension or like emotional disturbances which comprises administering to said )patient an effective dose of 2rmethyl-5-phenyl-l,2;-dihydro-3H-2-benzazepine or a pharmaceutically acceptable salt thereof.

4. A method as claimed in claim 3 in which the dose is given in the form of unit dose, each dose containing from 25-500 mg. of active ingredient to provide a daily dose of from 05-20 mg./kg. body weight.

References Cited J. Chem. Soc., 1969 (C), PP. 625-627.

STANLEY J. FRIEDMAN, Primary Examiner